Your browser doesn't support javascript.
loading
Tyrosine Kinase Inhibitor and Immune Checkpoint Inhibitor Responses in KIT-Mutant Metastatic Melanoma.
McKean, Meredith; Oba, Junna; Ma, Junsheng; Roth, Katherine G; Wang, Wei-Lien; Macedo, Mariana P; Carapeto, Fernando C L; Haydu, Lauren E; Siroy, Alan E; Vo, Phuong; Hong, David S; Eterovic, Agda K; Patel, Keyur Pravinchandra; Bassett, Roland L; Grimm, Elizabeth A; Lazar, Alexander J; Woodman, Scott E.
Afiliación
  • McKean M; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Oba J; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Ma J; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Roth KG; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, California.
  • Wang WL; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Macedo MP; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pathology, AC Camargo Cancer Center, São Paulo, Brazil.
  • Carapeto FCL; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Haydu LE; Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Siroy AE; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Pathology, Immunology, and Laboratory Medicine, University of Florida College of Medicine, Gainesville, Florida, USA.
  • Vo P; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Clinical Research Division, Fred Hutchinson Cancer Research Center and Division of Medical Oncology, University of Washington School of Medicine, Seattle, Washington, USA.
  • Hong DS; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Eterovic AK; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Patel KP; Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Bassett RL; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Grimm EA; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Lazar AJ; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center,
  • Woodman SE; Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA; Department of Systems Biology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Electronic address: swoodman@mdanderson.org.
J Invest Dermatol ; 139(3): 728-731, 2019 03.
Article en En | MEDLINE | ID: mdl-30798855
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Proteínas Proto-Oncogénicas c-kit / Inhibidores de Proteínas Quinasas / Melanoma / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Invest Dermatol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Cutáneas / Proteínas Proto-Oncogénicas c-kit / Inhibidores de Proteínas Quinasas / Melanoma / Antineoplásicos Tipo de estudio: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Male País/Región como asunto: America do norte Idioma: En Revista: J Invest Dermatol Año: 2019 Tipo del documento: Article País de afiliación: Estados Unidos Pais de publicación: Estados Unidos